173 related articles for article (PubMed ID: 31156170)
21. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study.
Coduras A; Rabasa I; Frank A; Bermejo-Pareja F; López-Pousa S; López-Arrieta JM; Del Llano J; León T; Rejas J
J Alzheimers Dis; 2010; 19(2):601-15. PubMed ID: 20110605
[TBL] [Abstract][Full Text] [Related]
22. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.
Wimo A; Winblad B; Stöffler A; Wirth Y; Möbius HJ
Pharmacoeconomics; 2003; 21(5):327-40. PubMed ID: 12627986
[TBL] [Abstract][Full Text] [Related]
23. Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1.
Robinson RL; Rentz DM; Andrews JS; Zagar A; Kim Y; Bruemmer V; Schwartz RL; Ye W; Fillit HM
J Alzheimers Dis; 2020; 75(2):437-450. PubMed ID: 32250304
[TBL] [Abstract][Full Text] [Related]
24. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
[TBL] [Abstract][Full Text] [Related]
25. Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.
Behrens S; Rattinger GB; Schwartz S; Matyi J; Sanders C; DeBerard MS; Lyketsos CG; Tschanz JT
Int Psychogeriatr; 2018 Oct; 30(10):1499-1507. PubMed ID: 29559029
[TBL] [Abstract][Full Text] [Related]
26. Determinants of costs of care for patients with Alzheimer's disease.
Jönsson L; Eriksdotter Jönhagen M; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A
Int J Geriatr Psychiatry; 2006 May; 21(5):449-59. PubMed ID: 16676288
[TBL] [Abstract][Full Text] [Related]
27. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
[TBL] [Abstract][Full Text] [Related]
28. Relationship between global severity of patients with Alzheimer's disease and costs of care in Spain; results from the co-dependence study in Spain.
Darbà J; Kaskens L; Lacey L
Eur J Health Econ; 2015 Nov; 16(8):895-905. PubMed ID: 25348897
[TBL] [Abstract][Full Text] [Related]
29. Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia.
Belger M; Haro JM; Reed C; Happich M; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
Eur J Health Econ; 2019 Apr; 20(3):343-355. PubMed ID: 30178148
[TBL] [Abstract][Full Text] [Related]
30. A Real-World Evidence Analysis of Associations Among Costs, Quality of Life, and Disease-Severity Indicators of Alzheimer's Disease in Thailand.
Kongpakwattana K; Dejthevaporn C; Krairit O; Dilokthornsakul P; Mohan D; Chaiyakunapruk N
Value Health; 2019 Oct; 22(10):1137-1145. PubMed ID: 31563256
[TBL] [Abstract][Full Text] [Related]
31. Burden and Strain among Familial Caregivers of Patients with Dementia in China.
Zhang M; Chang YP; Liu YJ; Gao L; Porock D
Issues Ment Health Nurs; 2018 May; 39(5):427-432. PubMed ID: 29775139
[TBL] [Abstract][Full Text] [Related]
32. Cost of Alzheimer's disease in a developing country setting.
Zencir M; Kuzu N; Beşer NG; Ergin A; Catak B; Sahiner T
Int J Geriatr Psychiatry; 2005 Jul; 20(7):616-22. PubMed ID: 16021668
[TBL] [Abstract][Full Text] [Related]
33. The Potential Impact of Alzheimer's Disease Early Treatment on Societal Costs of Care in Czechia: A Simulation Approach.
Broulikova HM; Sladek V; Arltova M; Cerny J
J Ment Health Policy Econ; 2018 Dec; 21(4):147-161. PubMed ID: 30676992
[TBL] [Abstract][Full Text] [Related]
34. What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.
Reed C; Happich M; Argimon JM; Haro JM; Wimo A; Bruno G; Dodel R; Jones RW; Vellas B; Belger M
J Alzheimers Dis; 2017; 57(3):797-812. PubMed ID: 28304285
[TBL] [Abstract][Full Text] [Related]
35. Economic impact of dementia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai, China.
Wang G; Cheng Q; Zhang S; Bai L; Zeng J; Cui PJ; Zhang T; Sun ZK; Ren RJ; Deng YL; Xu W; Wang Y; Chen SD
J Alzheimers Dis; 2008 Sep; 15(1):109-15. PubMed ID: 18780971
[TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics and longitudinal changes of informal cost of Alzheimer's disease in the community.
Zhu CW; Scarmeas N; Torgan R; Albert M; Brandt J; Blacker D; Sano M; Stern Y
J Am Geriatr Soc; 2006 Oct; 54(10):1596-602. PubMed ID: 17038080
[TBL] [Abstract][Full Text] [Related]
37. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
Marin D; Amaya K; Casciano R; Puder KL; Casciano J; Chang S; Snyder EH; Cheng I; Cuccia AJ
Int Psychogeriatr; 2003 Dec; 15(4):385-98. PubMed ID: 15000418
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of donepezil in moderate to severe Alzheimer disease.
Feldman H; Gauthier S; Hecker J; Vellas B; Hux M; Xu Y; Schwam EM; Shah S; Mastey V;
Neurology; 2004 Aug; 63(4):644-50. PubMed ID: 15326236
[TBL] [Abstract][Full Text] [Related]
39. The net cost of Alzheimer disease and related dementia: a population-based study of Georgia Medicaid recipients.
Martin BC; Ricci JF; Kotzan JA; Lang K; Menzin J
Alzheimer Dis Assoc Disord; 2000; 14(3):151-9. PubMed ID: 10994656
[TBL] [Abstract][Full Text] [Related]
40. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease.
Bergvall N; Brinck P; Eek D; Gustavsson A; Wimo A; Winblad B; Jönsson L
Int Psychogeriatr; 2011 Feb; 23(1):73-85. PubMed ID: 20619068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
